Biosimilars in Pharmaceuticals: Recombinant antibodies for cytotoxic T-cells
Powered by
Gain invaluable insights that can revolutionize your business
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating or maturing. This report specifically looks at biosimilars innovation in Recombinant antibodies for cytotoxic T-cells for the pharmaceuticals industry and the leading companies, start-ups and adoption trends. These insights help in making informed strategic decisions for a more durable source of competitive advantage
Note:
* This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
Decode the key disruptive innovations impacting the pharmaceuticals sector, with specific focus on Recombinant antibodies for cytotoxic T-cells and its trends in patent filing, identifying the leading companies and start-ups (and those with unicorn potential), key application areas plus examples from real-world scenarios and leading countries driving the innovation. In addition, we gauge the adoption trends in Recombinant antibodies for cytotoxic T-cells, by analyzing funding/investing trends, demand for human capital/jobs, social media buzz, company filings, and the latest news in the area
Key Highlights
Recombinant antibodies for cytotoxic T-cells: innovation landscape, patent filings trend, leading countries innovating, key application areas, top innovators, potential unicorns, real-world innovations, alternative dataset to track adoption trends using deals, jobs, social media, company filings, latest news, plus deep dive on key companies in Recombinant antibodies for cytotoxic T-cells
Reasons to Buy
• Identify emerging, accelerating, and maturing innovations in the sector likely to be disruptive in the future
• Evaluate key companies at the forefront of these innovations and their disruptive impact
• Discover key start-ups innovating in the area and uncover those with unicorn potential
• Build strategic technology / product roadmaps to stay ahead of disruption through actionable intelligence
Cellectis SA
Memorial Sloan Kettering Cancer Center
Gilead Sciences Inc
bluebird bio Inc
Autolus Limited
Amgen Inc
City of Hope
Fred Hutchinson Cancer Research Center
Eureka Therapeutics Inc
Miltenyi Biotec GmbH
CARsgen Therapeutics Ltd
Seattle Children's Hospital
Pfizer Inc
Regeneron Pharmaceuticals Inc
CRISPR Therapeutics AG
ImmunityBio Inc
Nanjing Legend Biotech Co Ltd
BioNTech SE
TCR2 Therapeutics Inc
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.